Harmony Biosciences Holdings, Inc.HRMY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · harmonybiosciences.com
Pharmaceutical company commercializing WAKIX (pitolisant) for narcolepsy and developing treatments for rare neurological diseases.
Key ratios
Operating cash flow growth
36.9%TTM
2025
58.4%2024
0.2%2023
51.9%
EPS growth
-0.2%TTM
2025
8.0%2024
17.8%2023
-28.3%
FCF / Sales
40.1%2025
2024
30.6%2023
37.6%
Net margin
18.9%TTM
2025
18.3%2024
20.4%2023
22.1%
ROA
11.6%TTM
2025
11.5%2024
13.2%2023
16.2%
ROE
20.5%TTM
2025
20.8%2024
25.8%2023
29.6%
Revenue growth
21.5%2025
2024
22.8%2023
32.9%
Track HRMY in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer